Success Metrics

Completion Rate

0%(0/1)

Active Trials

2(67%)

Terminated

1(33%)

Phase Distribution

Ph not_applicable

33%

Ph phase_1

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution2 total trials

Phase 1Safety & dosage

1(50.0%)

N/ANon-phased studies

1(50.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Terminated(1)

Detailed Status

Recruiting1

Active, not recruiting1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 1

Trials by Phase

Phase 11 (50.0%)

N/A1 (50.0%)

Trials by Status

recruiting133%

active_not_recruiting133%

terminated133%

Recent Activity

2 active trials

Showing 3 of 3

active_not_recruitingphase_1

Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy

NCT02204098

recruitingnot_applicable

Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment

NCT06574620

terminated

Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian Cancer

NCT01881451

Clinical Trials (3)

Showing 3 of 3 trials

NCT02204098Phase 1

Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy

Active Not Recruiting

NCT06574620Not Applicable

Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment

Recruiting

NCT01881451

Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian Cancer

Terminated

All 3 trials loaded

Drug Details

Intervention Type: PROCEDURE
Total Trials: 3